Analyst Update: Netflix, Heron Therapeutics, Healthways

Analysts adjusted their ratings on Netflix, Inc. (NASDAQ:NFLX), Heron Therapeutics Inc (NASDAQ:HRTX), and Healthways, Inc. (NASDAQ:HWAY)

by Karee Venema

Published on Jun 19, 2015 at 2:38 PM
Updated on Jun 29, 2020 at 3:32 PM

Analysts adjusted their ratings on streaming giant Netflix, Inc. (NASDAQ:NFLX), drugmaker Heron Therapeutics Inc (NASDAQ:HRTX), and health management solution specialist Healthways, Inc. (NASDAQ:HWAY). Here's a quick roundup of today's brokerage notes on NFLX, HRTX, and HWAY.

  • Oppenheimer boosted its price target on NFLX to $800 from $610, expecting the stock to rally into uncharted territory. The equity is failing to capitalize on the bullish brokerage note -- one of many it's received in recent weeks -- and was last seen off 0.3% at $661.33. This negative price action isn't necessarily unexpected, though. The stock has rallied almost 94% year-to-date, and hit a record high of $692.79 as recently as June 10. Even with Netflix, Inc.'s 4.5% decline from this notable milestone, the security's 14-day Relative Strength Index (RSI) is still hovering near overbought territory at 69 -- suggesting additional losses may be on the near-term horizon.

  • Leerink raised its price target on HRTX to $38 from $26. As a result, the security jumped to a five-year high of $32.96 out of the gate, but was more recently up 0.6% at $32.43. Longer term, the stock has been on fire in recent weeks, surging almost 163% since its May 28 close at $12.35 -- thanks to some upbeat drug data and analyst attention. Option traders have been hoping for additional gains, too. Specifically, over the past 10 sessions, speculators at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have bought to open 3.68 calls for each put on Heron Therapeutics Inc.

  • HWAY tumbled to an annual low of $12.02 -- and was last seen off 20.6% at $12.32 -- after the firm's downwardly revised 2015 revenue forecast was met with a round of bearish brokerage notes. Dougherty, for example, slashed its price target by $10 to $15, saying Healthways, Inc.'s looming challenges could be a reflection of poor leadership. Heading into today's session, the equity was already staring at a nearly 22% year-to-date deficit -- most likely to the delight of short sellers. Short interest edged up 3.6% in the last two reporting periods, and now accounts for 16.6% of HWAY's available float.

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter